Read More Pharma Industry News Halda Therapeutics joins Johnson & Johnson in $3bn cancer drug platform deal Johnson & Johnson acquires Halda Therapeutics for $3.05B. Find out why its RIPTAC platform could reshape prostate and solid tumor cancer treatment. byVenkateshJanuary 2, 2026